6 резултати
OBJECTIVE
To determine the efficacy and safety of single agent sorafenib, an oral multi-targeted tyrosine kinase inhibitor, in patients with advanced uterine carcinoma and carcinosarcoma.
METHODS
This multi-institutional non-randomized phase II trial enrolled two cohorts: patients with uterine
Our case was a 65-year-old male, with the chief complaints of diarrhea and abdominal distention. Three years earlier, the patient had undergone transcatheter arterial embolization and radiofrequency treatment based on a diagnosis of hepatocellular carcinoma due to hepatitis B by another doctor. In
OBJECTIVE
The purpose of this research was to assess the feasibility of administering Col-3, an oral chemically modified tetracycline derivative with potent inhibitory effects on matrix metalloproteinase activity and production, and recommend a dose on an uninterrupted once-daily schedule. The study
OBJECTIVE
Treatment options remain limited for women with relapsed/metastatic endometrial cancer (EC). Angiogenesis is one of the major components of tumor progression and thus an attractive target. The aim of this phase II trial was to assess the efficacy and tolerability of sunitinib, an oral
Uterine sarcoma is an aggressive tumor associated with poor survival, compared to endometrioid carcinoma. Postoperative local radiotherapy and chemotherapy are controversial.PATIENTS AND METHODS
We report a retrospective analysis of 14 patients with
The relevance of the MET/Hepatocyte Growth Factor (HGF) pathway in endometrial cancer tumor biology supports the clinical evaluation of cabozantinib in this disease.PHL86/NCI#9322 (NCT01935934) is a single arm study that evaluated cabozantinib in women with